Table 2.

Main properties of the most promising approaches to artificial blood products [5, 12, 38, 65, 80, 101, 105]

	Formulation	Mean droplet size	Major side effects
Fluosol-DA	14% PFD. 6% perfluorotripropylamine + 2.7% pluronic F-68 + 0.4% egg yolk phospholipid + 0.03% potassium oleate	0.12 μm	Transient drop in neutrophils and platelets, pneumonia [74, 80]
Perftoran	14% PFD. 6% perfluoromethylcyclohexylpiperidin + 6.5% proxanol 268 + egg yolk phospholipid	0.03–0.15 μm	Hypotension and pulmonary complications [61]
Oxygent	58% PFOB. 2% perfluorodecyl bromide + 3.6% egg yolk phospholipid	0.16 μm	Flu-like symptoms, stroke [49]
Oxycyte	60% tertbutylperfluorocyclohexane. Egg yolk phospholipid	0.2 μm	Flu-like symptoms [49]
DDFPe	2% DDFP. 5% human serum albumin	0.2 μm	Coughing, hypertension [12]
A-AOCs	17% PFD. 5% human serum albumin	0.35 μm	Results of clinical studies are not yet available [105]